Zhejiang Sanhua Seeks $1 Billion in Hong Kong Listing
Zhejiang Sanhua Intelligent Controls Co. is seeking to raise as much as HK$8.12 billion ($1 billion) in its Hong Kong listing, the latest billion-dollar deal to drive the city's recovery in share sales.
The Chinese company on Friday began taking investor orders for 360 million shares, according to listing document. Sanhua is offering the shares at HK$21.21 to HK$22.53 each and has the option to upsize the deal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Think Costco Wholesale Is Expensive? This Chart Might Change Your Mind.
Costco stock has delivered a 2,320% total return over the past 15 years. The company keeps growing its cash profits while earning increasingly strong returns on its business investments. Costco's ROIC even beats Amazon's in the asset-light e-commerce sector. 10 stocks we like better than Costco Wholesale › Warehouse retailer Costco Wholesale (NASDAQ: COST) may sell goods at affordable prices, but the stock is pretty expensive. Costco investors have pocketed a total return of 2,320% over the last 15 years, leaving the S&P 500 index far behind at a 663% gain. The stock traded at a luxurious 55.8 times trailing earnings on June 26, or 59.6 times free cash flow. So you wouldn't be the first investor to call Costco's stock "expensive." But you might change your mind when you look at the chart below. I'm about to show you a rare combination. Costco has a long-standing habit of growing its cash profits, while also making better and better use of the new capital over time. Free cash flow is the profit that's left over after paying off operating expenses and capital expenses. This capital can be used to finance dividend payouts, execute share buybacks, acquire smaller rivals, or boost the balance sheet's cash reserves. It's a measure of real cash profits, rather than the tax accounting construct you know as net profit or earnings. And Costco earns a lot of cash profits. Return on invested capital (ROIC) measures how effectively a company puts its profits to work. Costco's ROIC is nearly double the figures you see for Walmart (NYSE: WMT) or Target (NYSE: TGT) nowadays, and even exceeds Amazon's (NASDAQ: AMZN) ROIC in the asset-light e-commerce industry. The company also delivers consistently wider ROIC margins over time, while most retailers struggle to keep ROIC stable. As Costco pairs richer ROIC readings with growing cash flows, it keeps feeding a flywheel of constant business improvements. That's an incredibly shareholder-friendly combination. Before you buy stock in Costco Wholesale, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Costco Wholesale wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Anders Bylund has positions in Amazon and Walmart. The Motley Fool has positions in and recommends Amazon, Costco Wholesale, Target, and Walmart. The Motley Fool has a disclosure policy. Think Costco Wholesale Is Expensive? This Chart Might Change Your Mind. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
Yahoo
30 minutes ago
- Yahoo
Central Plains Bancshares Full Year 2025 Earnings: EPS: US$0.96 (vs US$2.19 in FY 2024)
Revenue: US$18.9m (up 9.6% from FY 2024). Net income: US$3.65m (down 2.8% from FY 2024). Profit margin: 19% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. EPS: US$0.96 (down from US$2.19 in FY 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Net interest margin (NIM): 3.56% (up from 3.36% in FY 2024). Non-performing loans: 0.36% (up from 0.17% in FY 2024). All figures shown in the chart above are for the trailing 12 month (TTM) period Central Plains Bancshares' share price is broadly unchanged from a week ago. It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Central Plains Bancshares, and understanding it should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
